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Abstract 
Wnt3a, one of Wnt family members, plays key roles in regulating pleiotropic cellular functions, including self‑renewal, 
proliferation, differentiation, and motility. Accumulating evidence has suggested that Wnt3a promotes or suppresses 
tumor progression via the canonical Wnt signaling pathway depending on cancer type. In addition, the roles of Wnt3a 
signaling can be inhibited by multiple proteins or chemicals. Herein, we summarize the latest findings on Wnt3a as an 
important therapeutic target in cancer.
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Background: the Wnt signaling pathway
The Wnt gene was first identified in 1982 and is named 
the Int gene in mice [1]. A subsequent study reported 
that the Int gene and wingless gene in Drosophila were 
homologous genes [2]. Therefore, both genes were rec-
ognized as the Wnt gene [3]. The Wnt family comprises 
19 human proteins, including Wnt1, Wnt2, Wnt2b 
(Wnt13), Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, 
Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt9a (Wnt14), Wnt9b 
(Wnt14b), Wnt10a, Wnt10b, Wnt11, and Wnt16. These 
genes encode secreted glycoproteins that are rich in 
cysteine [4]. Wnts can combine with cell membrane 
receptors that play a critical role in autocrine regulation 
and/or participate in paracrine modification by binding 
to adjacent cell membrane receptors. The signal trans-
duction pathway mediated by Wnt genes is called the 
Wnt signaling pathway.
The Wnt signaling pathway can be divided into canoni-
cal and noncanonical pathways. The canonical path-
way is also called the Wnt/β-catenin pathway (Fig.  1). 
The noncanonical pathway includes the  Wnt–planar 
cell polarity pathway  (Wnt-PCP pathway) and the Wnt-
calcium pathway (Wnt-Ca2+ pathway) [5]. According to 
the characteristics of its functions, the Wnt family can 
also be divided into two categories: Wnt1 and Wnt5a. 
The Wnt1 category includes Wnt1, Wnt2, Wnt2b, Wnt3, 
Wnt3a, Wnt7a, Wnt8, Wnt8b, and Wnt10a, which are 
involved in the canonical signaling pathway, whereas 
Wnt4, Wnt5a, and Wnt11 belong to the Wnt5a category 
and activate the noncanonical signaling pathway.
The canonical Wnt pathway begins with the binding of 
a Wnt ligand to its receptor Frizzled (Fz) and co-recep-
tor lipoprotein receptor-related protein (LRP5/6), which 
then activates the scaffold protein Disheveled (Dvl) and 
causes dissociation of the “destruction complex” formed 
with casein kinase 1 (CK1), glycogen synthase kinase-3β 
(GSK-3β), and the scaffolding proteins adenomatous 
polyposis coli (APC), Axin1, and Axin2 [6, 7]. The dis-
sociation of the “destruction complex” causes degrada-
tion of β-catenin, therefore inducing the cytoplasmic 
accumulation of β-catenin and its translocation into the 
nucleus to interact with T cell–specific transcription fac-
tor (TCF) and lymphoid enhancer-binding factor (LEF), 
which regulate the expression of Wnt target genes [6, 
7]. The Wnt/β-catenin signaling pathway is one of the 
most conserved pathways in organism evolution and 
plays key roles in embryonic development, cell growth, 
differentiation, polarity formation, neural develop-
ment, and carcinogenesis [8]. Aberrant activation of the 
Wnt/β-catenin signaling pathway has been implicated in 
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a wide variety of cancer types [9, 10], and β-catenin has 
been demonstrated to be a crucial factor for regulation 
of Wnt/β-catenin downstream target genes [9]. Nuclear 
accumulation of β-catenin has been recognized as a bio-
marker for cancer prognosis [11, 12].
Wnt3a in non‑cancer cell development
The Wnt3a gene, clustered on human chromosome 1q42 
[13], induces the accumulation of β-catenin, thereby acti-
vating the canonical Wnt signaling pathway [14]. It plays 
crucial roles in both proliferation and differentiation pro-
cesses in several types of stem cells, such as neural stem 
cells and hematopoietic stem cells. In addition, Wnt3a 
can stimulate the migration and invasion of tropho-
blasts [15] and induce the survival, proliferation, and 
migration of human embryonic kidney (HEK) 293 cells 
[16]. Wnt3a has also been shown to induce the migration, 
invasion, and colony formation of mouse mammary epi-
thelial HC11 cells [17]. In addition, Wnt3a can down-reg-
ulate E-cadherin expression and increase the proliferative 
potency of ovarian surface epithelium (OSE) cells [18]. 
Wnt3a promotes cell survival and the formation of sphe-
roids in colonic epithelial cells or crypts [19] and inhibits 
apoptosis in mouse embryonic liver stem cells, prolong-
ing their survival by up-regulating anti-apoptotic factors 
and down-regulating pro-apoptotic factors of the Bcl-2 
family [20]. Wnt3a up-regulates genes implicated in mel-
anocyte differentiation [21] and increases the expression 
and nuclear localization of the transcriptional co-acti-
vator with PDZ-binding motif (TAZ), a transcriptional 
Fig. 1 The canonical Wnt3a pathway. SULF-2 sulfatase 2, Ror2 an orphan receptor, belonging to the Ror family of receptor tyrosine kinases, MARCKs 
myristoylated alanine‑rich C‑kinase substrate, FAM129B family with sequence similarity 129, member B, FAK focal adhesion kinase, DKK1 Dickkopf‑
related protein 1, LRP5/6 lipoprotein receptor‑related protein 5/6, Dvl disheveled, GSK-3β glycogen synthase kinase‑3β, CK1 casein kinase 1, CtBP 
C‑terminal binding protein, PPARγ peroxisome proliferator‑activated receptor‑gamma, TCF T‑cell–specific transcription factor, LEF lymphoid 
enhancer‑binding factor, FRP frizzled‑related protein, Axin1/2 axis inhibition protein 1 and 2, APC adenomatous polyposis coli, FoxM1 forkhead box 
M1
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modulator that plays a key role in cell proliferation, dif-
ferentiation, and stem cell self-renewal, activating osteo-
blastic differentiation [22]. This process also induces 
osteoblastic differentiation and the expression of osteo-
protegerin (OPG) in osteoblast precursor C2C12 cells 
[23]. Furthermore, Wnt3a inhibits B lymphopoiesis and 
plasmacytoid dendritic cells but promotes the retention 
of hematopoietic stem cell markers, cell yields [24], and 
the self-renewal of hematopoietic stem cells [25]. Wnt3a 
suppresses the differentiation of mesenchymal stem cells 
into osteogenic or adipogenic lineages and Wnt3a-pro-
ducing TW3R feeder cells, providing a growth advan-
tage for undifferentiated human induced pluripotent 
stem cells (iPSC) and embryonic stem cells (ESCs) [26]. 
Wnt3a promotes the proliferation of human ESCs [27]. 
Wnt3a induces cell proliferation, morphological changes, 
and migration in C18-4 spermatogonial stem cells, and 
it maintains adult human embryonic stem (ES)-like cells 
derived from human germ cells in an undifferentiated 
stage, expressing essential human ES cell transcription 
factors [28]. Co-culture of Wnt3a-producing rat embry-
onic fibroblasts with human pre-B leukemia cell lines 
KM3 and REH significantly reduces Apo2L/TNF-related 
apoptosis-inducing ligand (TRAIL)-induced apoptosis of 
the lymphoid cells [29]. Wnt3a expression leads to sta-
bilization and nuclear accumulation of β-catenin in pri-
mary lineage-restricted B progenitor cells, suppresses B 
lymphopoiesis of CD133+CD10− hematopoietic progeni-
tor cells and CD10+ B progenitor cells, and suppresses 
cell division of B progenitor cells [30]. Wnt3a promotes 
c-Kit− cells to induce myeloid and erythroid progeni-
tors with robust self-renewal capacity. Wnt3a-stimulated 
c-Kit− cells induce all hematopoietic lineages (lymphoid, 
myeloid, and erythroid) upon transplantation into the 
liver of newborn recipient mice [31].
Wnt3a also plays important roles in organ formation. 
It can enhance cardiac myogenesis by increasing TCF-
dependent transcription and inducing cardiac-specific 
markers, bone morphogenetic proteins (BMPs), and sar-
comeric myosin heavy chains (MHC) [32]. Wnt3a has 
been shown to induce myogenesis in the myotome of the 
differentiating somite and the activation of myogenic dif-
ferentiation antigen (MyoD) expression and subsequent 
skeletal muscle development [33].
Wnt3a actives atypical protein kinase C ioys (pKCiota) 
and induces a punctate distribution of pKCiota in the 
neurites and cytoplasm, with a particularly intense signal 
at the centrosome [34]. Wnt3a serves as a crucial player 
in neuro-mesodermal stem cell maintenance and differ-
entiation [35]. Therefore, Wnt3a is involved in the forma-
tion of the nervous system.
It has been reported that Wnt3a induces produc-
tion of bone-protective OPG and alkaline phosphates 
in preosteoblastic C2C12 cells [36]. It can also induce 
natural killer T cell anergy to re-stimulate alpha-GalCer 
[37]. Wnt3a prevents the adverse effects of Lgr4 loss on 
organoid formation [38] and induces EphB4 in mesen-
chymal stem cells [39]. Wnt3a increases the percent-
age of CD34−CD7+ and CD34−CD7+cyCD3+ cells 
and the expression of CD3 epsilon and preT alpha [40]. 
Wnt3a overexpression is positively associated with 
ulcerative colitis versus noninflammatory bowel disease 
[41]. Wnt3a induced Fz1 expression in a normal colon 
mucosa–derived cell line in vitro [42]. It has been dem-
onstrated that Wnt3a mediates somitogenesis by activat-
ing a network of interacting target genes that promote 
mesodermal fate and position boundary determination 
genes, thus activating the segmentation clock in the ante-
rior presomitic mesoderm [35].
Wnt3a expression in tumors
Tumor development depends upon the interactions 
among environmental factors, cells in the tumor micro-
environment, and the genetic nature of tumor cells, lead-
ing to the disordered expression of oncogenes, tumor 
suppressor genes, and abnormal intracellular signal 
transduction pathways. Studies on intracellular signal 
transductions have become “hot” research fields in terms 
of tumorigenesis, invasion, and metastasis. Abnormal 
activation of the Wnt signaling pathway has been shown 
to be closely associated with tumor progression and be 
involved in various types of cancer. For example, Wnt3a 
is highly expressed in human scirrhous gastric carci-
noma 44As3 cells with highly metastatic derivatives [43], 
advanced prostate cancer cells [44], and activating tran-
scription factor (ATF3)-induced mammary tumors [45]. 
Wnt3a expression is higher in most breast cancer cell 
lines than in normal human mammary epithelial cells 
[46], which is also true in oral squamous cell carcinoma 
compared with control nonmalignant tissues [47]. In 
addition, Wnt3a expression is associated with the clini-
cal grade and aggressiveness of gliomas, and interestingly, 
it is overexpressed on glioma stem cells [48]. Wnt3a and 
Wnt3 mRNA were reported to be co-expressed in the 
embryonal carcinoma NT2 cell line and the breast cancer 
MCF-7 cell line [49].
Wnt3a suppresses or promotes cancer cell growth 
in vitro
Wnt3a can either suppress or promote cancer cell growth, 
depending upon cancer types. For example, Wnt3a sup-
presses the growth and proliferation of the lung and 
lacrimal gland [50], induces B-cell precursor acute 
lymphoblastic leukemia (B-ALL) cell death [51], and sup-
presses the proliferation of several B-ALL cell lines [52]. 
Wnt3a enhances TRAIL-dependent apoptosis in multiple 
Page 4 of 9He et al. Chin J Cancer  (2015) 34:50 
melanoma cell lines [53]. Wnt3a decreases proliferation 
rate and induces myogenic differentiation in alveolar 
rhabdomyosarcoma cells [54]. On the other hand, Wnt3a 
antagonizes the inhibition of the self-renewal of liver 
cancer stem cells induced by 8-bromo-7-methoxychry 
[55], promotes the self-renewal of leukemic stem/pro-
genitor cells in some acute myeloid leukemia and acute 
T-lymphoblastic leukemia cell lines [25], promotes the 
proliferation and survival of acute lymphoblastic leuke-
mia cells [56], reduces the anti-proliferative activity of 
lenalidomide multiple myeloma [57], and stimulates the 
proliferation of malignant mesothelioma cells [58]. More-
over, Wnt3a promotes the proliferation of breast cancer 
MCF7 cells [59] and increases the expression of high-
mobility group A protein 1 to maintain the proliferation 
of gastric cancer cells [60]. Wnt3a reverses docosahexae-
noic acid-induced growth inhibition in human pancreatic 
cancer PANC-1 cells [61]. Increased Wnt3a expression 
induces prostate cancer LNCaP cell proliferation, neu-
tralizing antibodies to reverse Wnt3a tumorigenesis [62]. 
Wnt3a can enhance hypoxia-induced epithelial-mesen-
chymal transition (EMT) in hepatocellular carcinoma 
(HCC) [63]. Wnt3a may play a key role in the mainte-
nance of NT2 cells in the undifferentiated proliferation 
stage [49]. When 4T1 cells are treated with recombinant 
Wnt3a along with quercetin, Wnt3a is able to restore the 
suppressed cell viability by quercetin [64]. Furthermore, 
Wnt3a treatment significantly decreases the drug suscep-
tibility of cholangiocarcinoma QBC939 cells to common 
chemotherapeutics [65], sensitizes malignant mesothe-
lioma cells to cytotoxic drugs [58], and induces striking 
morphological changes accompanied by the rearrange-
ment of the actin cytoskeleton in myeloma cells [66].
Wnt3a affects tumor growth in vivo
It has been reported that based on the expression of 
Wnt3a, erb-b2 receptor tyrosine kinase 3 (ERBB3), lym-
phocyte-specific protein tyrosine kinase (LCK), and Rho 
family GTPase 3 (RND3) to predict mortality, the four-
gene model achieved better predictive value than clini-
cal stage or tumor size in early-stage non–small cell lung 
cancer [67]. Wnt3a decreases metastases in a mouse 
melanoma model [68]. However, the Wnt3a transduced 
into HCC cells may promote cell cycle progression and 
accelerate tumor formation in athymic nude mice [69]. 
Co-injecting Wnt3a-expressing human mammary fibro-
blasts with human breast cancer cell lines into mouse 
mammary fat pads accelerates tumor growth [70]. Wnt3a 
treatment abolishes sorafenib-induced HCC growth inhi-
bition in vitro and in vivo [71]. Wnt3a-expressing H929 
cells injected into human bone exhibit increased osteo-
blast-to-osteoclast ratios and therefore reduce tumor 
burden. Likewise, treatment with recombinant Wnt3a 
stimulates bone formation and attenuates multiple 
myeloma cell growth in myelomatous severe combined 
immunodeficiency (SCID)-hu mice [72].
Wnt3a functions in cancer
Wnt3a modulates gene expression in cancer
The apoptosis signal-regulating kinase 1 (ASK1) pro-
tein expression level is reduced in L929 cells that stably 
express Wnt3a versus L929 control cells [73]. Wnt3a 
causes increased self-renewal and prostasphere size, 
which is associated with a significant increase in nuclear 
β-catenin, keratin 18, CD133, and CD44 expression in 
prostate cancer cells [74]. Wnt3a increases the level 
of forkhead box M1 (FoxM1), which binds directly to 
β-catenin, enhancing β-catenin nuclear localization and 
transcriptional activity in tumor cells [75], and increases 
prostaglandin E2 (PGE2) levels through very early 
15-hydroxyprostaglandin dehydrogenase (15-PGDH) 
suppression to promote colorectal tumorigenesis [76]. 
Wnt3a can enhance the expression and activity of phos-
pholipase D1 (PLD1; a cell survival mediator) in many 
types of cancer cells [77] and enhance the expression of 
PLDs at a transcriptional level, as shown in colorectal 
cancer HCT116 cells. PLD is necessary for the Wnt3a-
driven invasion and anchorage-independent growth 
of colon cancer cells [78]. Wnt3a induces BMP-4 and 
BMP-6 expression and their promoter activation in 
prostate cancer cells [79]. It significantly increases junc-
tion plakoglobin, interacts with sex-determining region 
Y-related high-mobility group box 4 (SOX4) in both the 
cytosol and the nucleus, and enhances the interaction 
between SOX4 and plakoglobin in prostate and breast 
cancer cells [80]. In prostate cells, Wnt3a can recruit 
the androgen receptor (AR) to the promoter regions 
of c-Myc and cyclin D1 [81]. Wnt3a either induces AR 
activity in the absence of androgen or enhances AR 
activity in the presence of low concentrations of andro-
gen, and significantly enhances growth of LNCaP cells in 
the absence of androgen [82]. Wnt3a expression is sig-
nificantly associated with lymph node involvement and 
matrix metallopeptidase-9 (MMP-9) expression in pri-
mary tumor, mesenchyme adjacent to tumor, and meta-
static sites in colorectal cancer [83]. It has been reported 
that the expression of the Wnt pathway genes is associ-
ated with estrogen receptor (ER) expression, and specific 
Wnt genes can predict relapse within specific subtypes of 
breast cancer. Wnt3a can increase mammosphere forma-
tion in ER-positive breast cancer cell lines; however, only 
ER-negative mammospheres are responsive to the ligand 
Wnt3a in patient-derived metastatic breast cancer sam-
ples [84].
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Wnt3a is regulated by genes/proteins in cancer
Sulfatase 2 (SULF2) increases Wnt3a expression in HCC 
cells, and xenografts established from SULF2-transfected 
Hep3B cells show increased Wnt3a levels in nude mice 
[85]. Dvl2 may increase prostate cancer growth and met-
astatic potential by up-regulating Wnt3a expression [86]. 
Ror2 positively modulates the Wnt3a-activated canonical 
Wnt signaling pathway in lung carcinoma H441 cells [87].
Potential inhibitors of Wnt3a signaling 
in preclinical studies
Increasing evidence has demonstrated that a number 
of proteins and chemicals can inhibit Wnt3a signaling 
in vitro and in vivo (Table 1).
Proteins
Knockdown of myristoylated alanine-rich C-kinase 
substrate (MARCKS)-related protein in EpRas mam-
mary epithelial cells reduces Wnt3a-induced TCF 
reporter signaling in vitro and causes loss of tumorigen-
esis in vivo [88]. Variant 3 of Collagen XVIII suppresses 
Wnt3a-induced stabilization of β-catenin and then 
down-regulates cyclin D1 and c-Myc to reduce tumor 
cell growth in colorectal and liver cancer cell lines [89]. 
Dickkopf-related protein 1 (DKK1) inhibits the Wnt3a-
regulated OPG and receptor activator of NF-kappaB 
ligand (RANKL) expression in osteoblasts, indirectly 
inducing osteoclast function [72, 90, 91]. DKK1 blocks 
Wnt3a-induced β-catenin accumulation in multiple 
Table 1 Potential inhibitors of Wnt3a
MARCKS myristoylated alanine-rich C-kinase substrate, FAK focal adhesion kinase, MEK mitogen activated and extracellular regulated kinase, HS20 a human 
monoclonal antibody against GPC3, GPC3 glypican-3, DKK1 Dickkopf-related protein 1, FAM129B family with sequence similarity 129, member B, RGS19 regulator of 
G-protein signaling 19
Tissue type Cell line(s) Potential inhibitor(s) of Wnt3a Reference(s)
Breast cancer EpRas
MDA‑MB‑231, T‑47D
MDA‑MB‑231
MCF‑7
Knockdown of MARCKS‑related protein
Niclosamide and silibinin
Kallistatin
Deep‑sea water
β‑estradiol
Knockdown of FAK protein
[88]
[111, 112]
[99]
[114]
[49]
[95]
Colon cancer SW480 MEK inhibitor PD98059, genistein, and wortmannin [100]
Gastric cancer Gastric cancer cells Receptor for activated protein kinase C [103]
Leukemia U937 Cordycepin [107]
Liver cancer Huh‑7 Variant 3 of collagen XVIII
HS20
[89]
[96]
Multiple myeloma OPM‑2, and MM patients’ plasma cells DKK1 [92]
Melanoma A375 and A2058 Loss of FAM129B [94]
Prostate cancer C4‑2B
PC‑3 and DU145
Axin
Niclosamide and silibinin
[79]
[111, 112]
Renal carcinoma ACHN Enhancer of zeste homolog 2 small interfering RNA [93]
Teratocarcinoma F9
NT2
RGS19
All‑trans‑retinoic acid
[104]
[115]
HEK293 HEK293 Etinoic acid
Variant 3 of collagen XVIII
Purified recombinant frizzled cysteine‑rich domain
MEK inhibitor PD98059, genistein, and wortmannin
Aspirin and norcantharidin
Hexachlorophene
Demethoxycurcumin and bisdemethoxycurcumin
Mesd C‑terminal region peptide and full‑length Mesd protein
A diterpenoid derivative, 15‑oxospiramilactone
Niclosamide and silibinin
Magnolo l
[49]
[89]
[98]
[100]
[108]
[109]
[110]
[105]
[106]
[111, 112]
[116]
Embryos Cytotrophoblasts
Neural plate
DKK1
Knockdown of FAK
[15]
[95]
B lymphopoiesis CD133+CD10−CD10+ cells DKK1 [30]
Fibroblasts NIH3T3 Chondroitin sulfate‑E [97]
Osteoblasts
Osteoblast‑like cells
Osteoblasts
Saos‑2, MG63, C2C12, and hFOB1.19
C2C12
DKK1
DKK1
Mesd C‑terminal region peptide
[90]
[91, 92]
[105]
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myeloma [92] and Wnt3a-mediated B lymphopoiesis 
of CD133+CD10− hematopoietic progenitor cells and 
CD10+ B progenitor cells [30]. Pre-treatment with 
recombinant DKK1 completely abolishes Wnt3a-induced 
OPG expression in mouse and human osteoblasts. 
Wnt3a-induced OPG expression could be diminished in 
osteoblasts co-cultured with a DKK1-expressing multi-
ple myeloma (MM) cell line or primary MM cells. DKK1 
blocks Wnt3a-stimulated trophoblast migration and 
invasion through matrigel and also reduces basal migra-
tion, invasion, and proliferation of cytotrophoblasts 
[15]. The enhancer of zeste homolog 2 small interfering 
RNA reduces the expression of Wnt3a and β-catenin in 
renal cell carcinoma and markedly inhibits the prolifera-
tion and invasion capabilities of human renal carcinoma 
ACHN cells [93]. FAM129B is needed for Wnt3a to 
activate a β-catenin–dependent reporter and decreases 
the ability of Wnt3a to increase the expression of the 
β-catenin target gene Axin2. Loss of FAM129B inhib-
ited the apoptosis of melanoma cells induced by Wnt3a 
[94]. Knockdown of focal adhesion kinase (FAK) down-
regulates Wnt3a gene expression in the neural plate [95]. 
HS20, a human monoclonal antibody against glypican-3 
(GPC3), blocks Wnt3a/β-catenin signaling. Moreover, 
HS20 inhibits Wnt3a-dependent cell proliferation in vitro 
and HCC xenograft growth in nude mice [96]. Chondroi-
tin sulfate-E decreases Wnt3a signaling through the neg-
ative regulation of LRP6 receptor activation in NIH3T3 
fibroblasts [97]. Purified recombinant frizzled cysteine-
rich domain inhibits Wnt3a-induced β-catenin activation 
in vitro [98]. Kallistatin inhibits the Wnt3a-induced pro-
liferation, migration, and invasion of breast cancer cells. 
Furthermore, kallistatin suppresses the Wnt3a-mediated 
phosphorylation of LRP6 and GSK-3β and the elevation 
of cytosolic β-catenin levels. Kallistatin has been shown 
to antagonize the expression of Wnt3a-induced target 
genes, including c-Myc, cyclin D1, and vascular endothe-
lial growth factor (VEGF) [99]. The mitogen activated and 
extracellular regulated kinase (MEK) inhibitor PD98059, 
genistein, and wortmannin effectively suppress Wnt3a/
β-catenin–regulated transcriptional activities as well 
as the intracellular accumulation of β-catenin protein 
in human colon cancer cells [100]. Axin blocks Wnt3a’s 
induction of BMP promoters in prostate cancer C4-2B 
cells [79]. Small interfering RNA of LRP5/6, secreted 
frizzled-related protein  2 (sFRP2), or sFRP5 potently 
reduce Wnt3a-mediated β-catenin accumulation [101]. 
The protein kinase N1 inhibits Wnt/β-catenin signaling 
and sensitizes melanoma cells to cell death stimulated by 
Wnt3a [102]. The receptor for activated protein kinase C 
inhibits Wnt3a signaling by inhibiting the recruitment of 
Axin by Dvl2 and by stabilizing the β-catenin destruction 
complex and acts as a tumor suppressor in gastric cancer 
cells [103]. Regulator of G-protein signaling 19 (RGS19) 
specifically reduces Wnt-responsive gene transcription 
in time-dependent and dose-dependent manners and 
blocks Wnt3a-induced cytosolic β-catenin accumulation, 
Dvl3 phosphorylation, and the formation of primitive 
endoderm [104]. The Mesd C-terminal region peptide 
and the full-length Mesd protein block Wnt3a-induced 
Wnt/β-catenin signaling in LRP5- and LRP6-expressing 
cells, inhibit Wnt/β-catenin signaling in human breast 
HS578T cells and prostate cancer PC-3 cells, and inhibit 
cancer cell proliferation [105].
Chemicals
The diterpenoid derivative 15-oxospiramilactone sup-
presses Wnt3a-stimulated top-flash reporter activity in 
HEK293T cells and inhibits the growth of colon cancer 
SW480 and Caco-2 cells [106]. Cordycepin suppresses 
the effect of Wnt3a-induced β-catenin in leukemia cells 
[107]. Norcantharidin reduces 80% of Wnt3a-induced 
β-catenin binding with lymphoid enhancer factor/T-cell 
factor protein [108]. Hexachlorophene antagonizes the 
Wnt3a-induced β-catenin response transcription (CRT) 
by promoting the degradation of β-catenin. In addition, 
hexachlorophene represses the expression of cyclin D1 
and inhibits the growth of colon cancer cells [109]. Dem-
ethoxycurcumin and bisdemethoxycurcumin suppress 
β-catenin transcription activated by Wnt3a-conditioned 
medium and inhibit the growth of various colon can-
cer cells [110]. Niclosamide and silibinin inhibit LRP6 
expression and phosphorylation, block Wnt3a-induced 
β-catenin accumulation, and inhibit Wnt/β-catenin sign-
aling in HEK293 cells, prostate cancer PC-3 and DU145 
cells, and breast cancer MDA-MB-231 and T-47D cells 
[111, 112]. Verapamil improves Wnt3a-induced loss of 
proteoglycan in chondrogenically differentiated ATDC5 
cells [113].
Furthermore, retinoic acid can reduce Wnt3a mRNA 
expression in NT2 cells. Wnt3a expression is down-
regulated by β-estradiol in MCF-7 cells [49]. Deep-sea 
water treatment results in a concomitant decrease in 
mRNA levels of MMP-9, transforming growth factor-β 
(TGF-β), Wnt5a, and Wnt3a in human breast cancer 
MDA-MB-231 cells [114]. All-trans-retinoic acid down-
regulates the expression of Wnt3a, Wnt8a, Wnt8b, 
Wnt10b, and Wn11 in NT2 cells [115]. Magnolol inhibits 
Wnt3a-induced β-catenin translocation and subsequent 
target gene expression in human embryonic kidney 293 
cells [116].
Conclusions
Wnt3a, an important member of the Wnt family, acti-
vates the canonical Wnt signaling pathway to exhibit its 
biological functions. It is mainly involved in embryonic 
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development, neural development, cell differentiation, 
proliferation, and tumorigenesis. Overall, our under-
standing of Wnt3a is incomplete, and molecular mecha-
nisms of its specific roles remain to be further studied in 
various diseases, including cancer.
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